Filtered By:
Specialty: International Medicine & Public Health
Drug: Pradaxa
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 25 results found since Jan 2013.
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
Traditionally, warfarin has been used to prevent stroke in patients with atrial fibrillation (AF), but data from large, multinational, prospective, randomized studies suggest that novel oral anticoagulants (NOACs) may be suitable alternatives. These include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. These data showed that dabigatran 150 mg twice daily was more effective at preventing stroke than warfarin, with similar rates of major bleeding, while rivaroxaban 20 mg once daily was noninferior to warfarin, with no difference in major bleeding rates. In addition...
Source: International Archives of Medicine - October 31, 2013 Category: Global & Universal Authors: Bruce Stambler Source Type: research
Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research
PM198 Antithrombotic Treatment in Relation to Age and Stroke Risk in Patients With Newly Diagnosed Atrial Fibrillation (Gloria-AF Phase II)
Vitamin K antagonists (VKAs) or the non-VKA oral anticoagulants (NOACs) are recommended for prevention of stroke in patients with atrial fibrillation (AF) and additional stroke risk factors. Phase II of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) started after approval of dabigatran etexilate, the first NOAC available for stroke prevention in patients with AF.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: J. Halperin, M. Huisman, H.-C. Diener, S. Dubner, C. Ma, K. Rothman, J. Healey, K. Zint, C. Teutsch, G. Lip Tags: Poster Abstract Source Type: research
Medicare beneficiary out-of-pocket spending for stroke prevention in non-valvular Atrial Fibrillation: a budget analysis
Healthcare costs today are increasingly being shifted from payers to patients, yet few providers factor patient costs into treatment decisions. Recent advancements in stroke prevention in atrial fibrillation (AF) have resulted in new treatment options where previously there were few. While the clinical benefit and cost effectiveness of these treatments are supported by a growing body of evidence, the cost impact to patients has not been explored. This analysis sought to quantify patient out-of-pocket costs for three stroke prevention strategies: warfarin, dabigatran and left atrial appendage closure (LAAC) with the Watchman Device.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: S. Armstrong, S.L. Amorosi, G. Erickson, P. Patel, K. Stein Source Type: research
Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives
Conclusions Dabigatran use improves patient survival and quality of life compared with warfarin. This represents the best therapeutic option in terms of cost and effectiveness in the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Source: Value in Health Regional Issues - June 10, 2015 Category: Global & Universal Source Type: research
Critical Appraisal Of Network Meta-Analyses Evaluating The Efficacy And Safety Of New Oral Anticoagulants In Atrial Fibrillation Stroke Prevention Trials
To critically appraise the published network meta-analyses (NMAs) evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, rivaroxaban and apixaban for the prevention of stroke in patients with non-valvular atrial fibrillation (AF).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: S. Cope, A. Clemens, F. Hammès, H. Noack, J. Jansen Source Type: research
Setting up the Right Scenarios for Cost-Effectiveness Analysis: An Example with Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients in China
Warfarin, the standard oral anticoagulant for stroke prevention in patients with atrial fibrillation (AF), is associated with frequent international normalized ratio (INR) monitoring and increased hemorrhagic risk. About 50% of European and American AF patients received warfarin nevertheless. Dabigatran, a novel oral anticoagulant, had been compared to warfarin to demonstrate its cost-effectiveness in developed countries. However, these economic evaluations couldn’t be applied to China setting. Despite treatment guidelines, warfarin use was conservative in China accounting for only 2.7% AF patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: Y. Wan, Z.G. Lu, F. Chen, J. Chen Source Type: research
Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials
To critically appraise published network meta-analyses (NMAs) evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, rivaroxaban, and apixaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF).
Source: Value in Health - January 28, 2015 Category: Global & Universal Authors: Shannon Cope, Andreas Clemens, Florence Hammès, Herbert Noack, Jeroen P. Jansen Source Type: research
Economic Evaluation Of Dabigatran Etexilate Versus Warfarin, Rivaroxaban And Apixaban In Stroke Prevention In Atrial Fibrilation
To determine the economic value of dabigatran for stroke prevention in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants warfarin, rivaroxaban and apixaban from a perspective of Mexican public institutions.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J.L. Huicochea-Bartelt, J. Gay-Molina, L.A. Ortiz-Blas, S. Herran Source Type: research
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants And Warfarin for Stroke Prevention In Atrial Fibrillation In Venezuela
Apixaban (5 mg BID), dabigatran (150mg), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Venezuela.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: Y Fernández Ávila, KC Garcia, S Garrido Lecca, BM Donato, A Juarez-Garcia Source Type: research
Adherence to Dabigatran and the Risk of Stroke
To determine if poor adherence to dabigatran is associated with an increased risk of stroke.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: TC Cheetham, Z Bider-Canfield, K Reynolds Source Type: research
Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstan
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: A Kostyuk, A Almadiyeva, T Nurgozhin Source Type: research
Preliminary Study of Safety and Efficacy of Warfarin Versus Dabigatran in Atrial Fibrillation Patients in a Tertiary Hospital in Malaysia
This study aims to compare the pattern of anticoagulants used and to assess their safety and efficacy by evaluating bleeding and stroke occurrences in both groups.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Mohd Hajiri, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research
Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol
DiscussionCurrent guidelines in the treatment of cerebral vein thrombosis dating back to 2011 from the American Heart Association/American Stroke Association endorse the utility of anticoagulation for the treatment of cerebral vein thrombosis; however, they did not support the use of direct oral anticoagulants. Updated guidelines from the European Stroke Organization, endorsed by the European Academy of Neurology in 2017, also refute utilization of direct oral anticoagulants due to a lack of evidence. There have been nearly 10 years of experience with direct oral anticoagulants in the treatment of venous thrombosis and ...
Source: Systematic Reviews - April 17, 2019 Category: International Medicine & Public Health Source Type: research
The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research
